USA-based Medicus Pharma has announced a positive-trending interim analysis for the SKNJCT-003 Phase II study, which aims to treat non-invasively basal cell carcinoma of the skin (BCC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback